TEVA

19°

Weather

YnetGlobal Channels

Sites & Sources

more channels

Contact

TEVA

Teva regains investment-grade rating from Fitch

Fitch points to expected growth from drugs including Austedo and Ajovy; Teva is still rated below investment grade by S&P Global Ratings, at BB+ with a stable outlook, and by Moody’s, at Ba1 with a positive outlook

ynet Global | 05.18.26

ריצ'רד פרנסיס, נשיא ומנכ"ל טבע, במפגש העיתונאים

Teva resumes acquisitions with $900 million Emalex deal after decade-long hiatus

Teva will pay $700 million upfront and up to $200 million more for Emalex, which develops a Tourette syndrome treatment granted orphan drug status; the deal comes as the company reports $4 billion in quarterly revenue and $369 million in net profit, beating forecasts

Navit Zomer | 04.29.26

From Netanya labs to global race: Teva develops antibody targeting celiac and autoimmune diseases

Backed by up to $500 million deal, Teva advances experimental antibody for celiac and vitiligo, aiming to stop autoimmune disease at its source; researcher offers rare look inside complex path from lab to patients

Eitan Gefen | 04.07.26

Teva shares slide as 2026 forecast disappoints despite strong 2025 earnings

Israel-based pharma giant posts $17.3 billion in 2025 revenue and 19% profit growth, but stock falls on lower-than-expected 2026 outlook, even as CEO touts pipeline potential and billion-dollar quarter from flagship drugs

Navit Zomer | 01.28.26

Teva’s billion-dollar bet to treat celiac and vitiligo

Teva is investing up to $500 million in a new antibody it hopes can transform treatment for vitiligo and celiac disease, two autoimmune conditions with limited options and major unmet medical needs

Tzur Gueta | 01.13.26

Teva, Royalty Pharma announce $500M deal to advance autoimmune drug

New partnership aimed at advancing Israeli pharma giant's anti-IL-15 drug for autoimmune diseases; CEO Richard Francis to detail growth strategy and pipeline progress at J.P. Morgan Healthcare Conference on Jan. 13

ynet Global | 01.12.26

Teva launches new global innovation program, will fully fund startup pilots

Teva is opening a call for startups in Israel and abroad as part of its new Rise program, offering full funding for pilots, rapid integration and support across seven innovation domains, in a move to accelerate drug development and supply-chain efficiency

Tal Shahaf | 11.20.25

רופאה ד"ר ריטה סגנטיני והאחות ג'וליה קקאצ'י זרקו תרופות של טבע באיטליה

Italian Jewish Medical Association demands action after hospital staff film anti-Israel Teva drug disposal

Dr. Daniel Radzik says letters to Health Minister and hospital were necessary to force apology after Tuscany medical staff filmed anti-Israel video; calls incident part of growing antisemitic climate across Europe; 'Medicines must not be used as tools of political or ideological dispute'

Ynetnews | 08.21.25

Outrage in Italy after medical staff seen discarding Israeli-made Teva medications

Protest targeting Israeli pharmaceutical giant Teva comes amid rising anti-Israel sentiment in Italy; pair later apologize, calling it 'a symbolic gesture for peace' and claiming no medicine actually discarded

Daniel Bettini | 08.20.25

Acamol, a household name in Israel, will now be made in Ulm; while prices remain steady, capsule counts will change; company says Israeli staff will focus on complex drugs and no jobs will be cut

Navit Zomer | 08.05.25

Trump’s drug price cuts hit Teva at a tough time

Israeli pharmaceutical giant recently announced plans to cut 8% of its global workforce and U.S. push for lower drug prices could trigger further layoffs

Sophie Shulman | 05.13.25

Hundreds of Israeli workers could be affected by Teva layoffs

Analysis: The pharmaceutical giant has announced an 8% cut in its workforce to improve efficiency; About 300 employees in Israel are expected to be laid off. While investors are pleased with the promise of reaching a 30% operating profit, employees may find that this is just the first 'big step' in a series of cuts

Sophie Shulman, Calcalist | 05.08.25

Teva to lay off 2,900 employees by 2027 - about 8% of workforce

Company will embark on a large-scale layoff process over the next two years and will also cut expenses to increase operating profit; Revenue in the first quarter was $3.89 billion, slightly below forecasts, but net income came in at 52 cents per share, above expectations; Its main drug, Austedo, generated higher-than-expected revenue

Sophie Shulman, Calcalist | 05.07.25

Teva shares jump by 26% on Wall Street as its most promising drug shows exceptional trial results

Duvakitug, a treatment for colitis and Crohn's disease, surpassed expectations and positions Teva to compete in the $28 billion global inflammatory bowel disease market

Sophie Shulman | 12.17.24

Teva Q2 results stronger than expected

The pharmaceutical company reports revenue of $4.2 billion and earnings of 61 cents per share. Austedo, Teva's strongest drug, designed to treat Dyskinesia, grew by 32% and generated revenues of $407 million

Sophie Shulman, Calcalist | 08.01.24

Hot Tags

Today

This Week

This Month

actress Ahmad al-Sharaa AI airport Ali Larijani American Jewish Committee Anthropic Antisemitism Arab Israelis arms sales

Hot Tags

Today

This Week

This Month

actress Ahmad al-Sharaa AI airport Ali Larijani American Jewish Committee Anthropic Antisemitism Arab Israelis arms sales